



Advances and Challenges of Stem-Cell-Based Therapy for CNS Disorders

Guest Editors:

Dr. Ana Marote

Dr. Nuno A. Silva

Dr. António Salgado

Deadline for manuscript
submissions:
closed (30 June 2023)

Message from the Guest Editors

Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. Due to the central nervous system's (CNS) limited capacity to spontaneously regenerate, few therapeutic approaches are available for CNS disorders, which can either be caused by disease or injury.

In recent decades, stem cells have been put forward as a promising tool for CNS regenerative medicine. The advent of cell reprogramming has allowed the generation of induced pluripotent stem cells (iPSCs), overcoming the ethical and legal issues associated with the use of human embryonic stem cells. Since then, iPSCs have been established as one of the most relevant cell sources for the generation of tissue-specific cell types for cell replacement therapies.

This Special Issue aims to compile experimental studies and reviews addressing the effects of pluripotent and multipotent stem cells for CNS disorders in preclinical models, and discussing the challenges of their use in future clinical applications.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)